Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770284 | 0.81 | TRPV4 (0.48) | CCR2TRPV4MCL1ALDH1A1KDM4E | |
| SCHEMBL3767971 | 0.79 | CA1 (0.46) | MCL1ALDH1A1TSHRHPGDALOX15 | |
| SCHEMBL4589791 | 0.78 | MCL1 (0.56) | CCR2MCL1ALDH1A1KDM4ETSHR | |
| SCHEMBL31239603 | 0.78 | MCL1 (0.56) | CCR2MCL1ALDH1A1KDM4ETSHR | |
| SCHEMBL8406304 | 0.77 | CDK1 (0.51) | CCR2TRPV4ALDH1A1L3MBTL1 | |
| SCHEMBL4012968 | 0.77 | CCR2 (0.56) | CCR2TRPV4L3MBTL1 | |
| SCHEMBL30762457 | 0.77 | CCR2 (0.56) | CCR2TRPV4L3MBTL1 | |
| SCHEMBL23148806 | 0.75 | TSHR (0.53) | CCR2TRPV4ADRA2AADRA2CADRA1D | |
| SCHEMBL11037064 | 0.75 | CYP3A4 (0.48) | CCR2TRPV4ADRA2AADRA2CADRA1D | |
| SCHEMBL30019925 | 0.75 | TSHR (0.53) | CCR2TRPV4ADRA2AADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | CCR2 131/4885TRPV4 2578/4885ADRA2A 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.